

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 March 2003 (06.03.2003)

PCT

(10) International Publication Number
WO 03/017981 A1

- (51) International Patent Classification⁷: **A61K 9/20**, 31/7048
- (74) Common Representative: **RANBAXY LABORATORIES LIMITED**; DESHMUKH, Jayadeep R., 600 College Road East, Suite 2100, Princeton, NJ 08540 (US).
- (21) International Application Number: **PCT/IB02/00175**
- (22) International Filing Date: 22 January 2002 (22.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PCT/IB01/01564 29 August 2001 (29.08.2001) IB
- (71) Applicant (*for all designated States except US*): **RANBAXY LABORATORIES LIMITED** [IN/IN]; 19, Nehru Place, 110 019 New Delhi, New Delhi (IN).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **RAMPAL, Ashok** [IN/IN]; 14, Sewa Nagar, Ram Tirath Road, 143001 Amritsar, Punjab (IN). **RAGHUVANSHI, Rajeev, S.** [IN/IN]; Flat No. 8131, Block: D-8, Vasant Kunj, 110070 New Delhi, New Delhi (IN). **KUMAR, Manoj** [IN/IN]; Mr. O.P. Ahuja, H. No. 157, Sector 16A, 122001 Faridabad, Haryana (IN).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: CONTROLLED RELEASE FORMULATION OF CLARITHROMYCIN OR TINIDAZOL

(57) Abstract: The present invention relates to a controlled release pharmaceutical composition comprising amounts ranging from about 0.1 to about 4.5% w/w, of one or more of rate controlling cellulosic ether polymers.



WO 03/017981 A1

CONTROLLED RELEASE FORMULATION OF CLARITHROMYCIN OR TINIDAZOL

Field of the Invention

5 The present invention relates to a controlled release pharmaceutical composition comprising amounts ranging from about 0.1 to about 4.5% w/w, of one or more of rate controlling cellulosic ether polymers.

Background of the Invention

10

 It is well known to those skilled in the art that controlled release formulations which are effective in maintaining therapeutic blood levels over extended periods to time result in optimal therapy. They not only reduce the frequency of dosing for enhanced patient convenience and compliance, but they also reduce the severity and frequency of side effects, as they maintain substantially constant blood levels and avoid fluctuations associated with conventional immediate release formulations administered three to four times a day. It is however very difficult to develop controlled release formulations of high dose drugs due to the unacceptably large sizes of the finished dosage form.

20

 In an effort to overcome the problem of size and patient compliance, Abbott has marketed its clarithromycin extended release tablets "Biaxin XL™" as two 500 mg strength tablets to be administered together once a day. Each 500 mg strength tablet weighs around 1000 mg. In their U.S. Patent No. 6,010,718 Abbott have claimed formulations containing 5% - 50% by weight of total polymer. The specification and examples of this patent discloses preferred formulations containing 10%-20% by weight of rate controlling polymer in the formulation in addition to other excipients. The formulation disclosed in this patent has a total tablet weight of about 1000 mg for a tablet containing 500 mg clarithromycin. A tablet containing 1000 mg drug when made in accordance with this invention would therefore be unacceptably large at 2000 mg.

U.S. Patent No. 5,705,190 describes controlled release compositions for poorly soluble basic drugs comprising a water soluble alginate salt, a complex salt of alginic acid and an organic carboxylic acid to facilitate dissolution of the basic drug at a high pH. The examples disclosed in this patent describe formulations
5 containing 10 - 20% w/w of rate controlling polymer. The total tablet weight of each tablet containing 500 mg drug as described in the examples of this invention is more than 900 mg, as substantial amounts of polymers are required for controlling the rate of drug release. A single tablet containing 1000 mg drug, when made according to this invention would weigh at least 1800 mg. This would be
10 unacceptably large for human consumption.

U.S. Patent No. 4,389,393 describes sustained release therapeutic composition using less than about one third of the weight of the solid unit dosage form, of hydroxypropyl methyl cellulose or a mixture of hydroxypropyl
15 methylcellulose with certain other rate controlling polymers. In the specification of this patent, the inventors disclose that they have been able to achieve sustained release from solid dosage forms containing as little as 5 to about 30 weight percent of these hydroxypropyl methylcelluloses. All the examples disclose compositions containing 9% or more of the rate controlling polymer.

20

Accordingly, none of the oral controlled drug delivery systems heretofore described is completely satisfactory for the delivery of high dose drugs with low water solubility.

25 It has now surprisingly been found that high dose drugs with low water solubility when formulated with amounts ranging from about 0.1% to about 4.5% w/w of one or more high viscosity cellulosic ether polymers resulted in extended release formulations which release the drug over an extended period of time.

30 Clarithromycin when formulated with amounts ranging from 0.1% to about 4.5% w/w of one or more high viscosity hydroxypropyl methylcellulose polymers resulted in extended release formulations wherein the area under the concentration time -curve and the maximum plasma concentration are within the interval 0.80-

1.25 when compared with two tablets of Biaxin XL® administered together as approved by the United States Food and Drug Administration (US FDA).

5 The use of the claimed amounts of rate controlling polymers not only ensures a more economical formulation compared to one made using larger amounts of polymers, it also ensures better patient compliance as patients have to take only one tablet instead of two tablets together.

Summary of the Invention

10

It is an object of the present invention to provide a controlled release formulation suitable for once daily administration, comprising a pharmaceutically effective amount of at least one drug having a water solubility of less than one part per 30 parts water, and from about 0.1% to about 4.5 % w/w of one or more rate
15 controlling high viscosity cellulosic ether polymers.

The present invention may apply also to even less soluble drugs for example up to a solubility of one part in 10,000 parts water.

20

Although, the invention is particularly suitable for high dose drugs but it can advantageously be used for low dose drugs as well, wherein use of small amounts of polymers will result in a more economical formulation.

25

It is further object of the present invention to provide a controlled release formulation for once daily administration of high dose drugs with low water solubility, wherein the formulation is of an acceptable size and is convenient for oral administration. The use of small amounts of polymers ensures that total weight of the dosage form is low and a single dosage unit is sufficient to provide therapeutic dosage of the drug even when the dosage form has to carry a high payload of the
30 drug. The present formulation provides obvious benefits with respect to small tablets which are more economical and easier to administer therefore ensuring better patient convenience and thereby patient compliance.

The drugs used in accordance with the present invention may be present at a dosage range of about 100-1500 mg. They include, but are not limited to those belonging to the class of :

- 5 Analgesics such as Etodolac, Fenoprofen, Tramadol, Paracetamol, Ibuprofen, Mefenamic acid, Naproxen etc.
- Anthelmintics such as Albendazole, Thiabendazole etc.
- Cardiovascular drugs such as Chlorothiazide, Dipyridamole etc.
- Antibacterials such as Ciprofloxacin, Erythromycin and its derivatives, Norfloxacin
- 10 Cefaclor, Cefpodoxime, Cefuroxime, Cefalexin and the like.
- Bronchodilators / anti-asthmatics such as Doxofylline, Zileuton, Theophylline etc.
- Gastrointestinal drugs such as Cimetidine and Mesalamine,
- Oral Antidiabetics such as Tolbutamide and Tolazamide,
- Antiprotozoals such as Tinidazole, Nifuratel, Ornidazole, Secnidazole etc.
- 15 Antivirals such as Aciclovir
- Antiepileptics such as Carbamazepine, Felbamate, Methoin etc.

- The cellulosic ether polymers which are effective in the present invention include, but are not limited to hydroxypropyl methylcellulose, hydroxyethyl cellulose,
- 20 hydroxypropyl cellulose and carboxy methylcellulose polymers. They are all commercially available in a wide variety of viscosity grades which can be used either alone or in combination with other cellulosic ether polymers.

- Hydroxypropylmethyl cellulose polymers are commercially available in
- 25 different viscosity grades. These include 4000 and 15000 cps viscosity grades of Methocel K i.e. Methocel K4M and Methocel K15M available from the Dow Chemical Co, USA and 4000, 15,000 and 39000 cps viscosity grades of Metalose 90 SH available from Shin Etsu Ltd, Japan, the 5,000, 12,000 and 75,000 cps viscosity grades of Methocel J i.e. Metocel JSM, J12M, J20M and J75M, available
- 30 from Dow Chemical Co and high viscosity grades of Methocel E available from Dow Chemical Co., USA.

One or more hydroxypropyl methylcelluloses having a viscosity of 4000 cps or more can be used as the sole carrier base material or in admixture with other cellulosic ether polymers of the same or higher viscosity.

- 5 Hydroxypropyl celluloses are commercially available in a wide range of viscosity grades under the trade name of Klucel® from Nippon Soda, Japan.

In addition to the drug and rate controlling cellulosic ether polymers, the composition may contain about 6 to 50% w/w of other pharmaceutically acceptable
10 excipients such as fillers, binders, and lubricants.

The composition according to the present invention contains fillers selected from amongst those conventionally used in the art such as celluloses, monosaccharides e.g. lactose and glucose; disaccharides e.g. sucrose;
15 polysaccharides e.g. mannitol; silicic acid, and mixtures thereof. Fillers are preferably present at about 5% to about 15% by weight of the formulation.

The composition according to the present invention may also contain binders selected from amongst those conventionally known in the art such as polyvinyl
20 pyrrolidone, sucrose, low viscosity hydroxypropyl methylcellulose, and the like.

The pharmaceutically acceptable lubricants in accordance to the present invention are selected from amongst talc, calcium stearate, magnesium stearate, polyethylene glycol, colloidal silicon dioxide, sodium stearyl fumarate and mixtures
25 thereof.

According to the present invention, the described pharmaceutical composition can incorporate a high dose medicament. The amount of the drug used in the composition can be as high as 1300 mg and the total weight of the
30 tablet does not exceed 1500 mg. The final tablet weight of a formulation containing 1000 mg drug is preferably 1300 mg. Thus the tablets made in accordance to the present invention are unique as they carry a very high payload of the drug and use

very small amounts of polymers for controlling the drug release while maintaining the integrity of the tablet.

The composition made according to the present invention may be formulated as a capsule or a tablet. Most preferably, the composition is a tablet. The tablet may optionally be coated with a thin layer of a film forming polymer or a pharmaceutical excipient.

The composition made in accordance with the present invention are further exemplified and illustrated herein.

EXAMPLE 1

The present example relates to a controlled release tablet formulation of tinidazole made using 2.37% of total rate controlling cellulosic ether polymer (a mixture of hydroxypropyl methylcellulose of viscosity 15,000 cps and 4,000 cps commercially available under the trade name of Methocel K15 MCR[®] and Methocel K4 MCR[®], respectively).

Table 1.1

Ingredients	mg/tablet	Percent w/w of composition
Tinidazole	1000.0	87.1
Methocel K15 MCR [®]	17.5	1.5
Methocel K4 MCR [®]	10.0	0.87
Lactose	50.0	4.36
Polyvinylpyrrolidone K30	25.0	2.18
Talc	10.0	0.87
Colloidal Silicon Dioxide	5.0	0.44
Sodium stearyl fumarate	31.5	2.74
Magnesium stearate	1.0	0.1
Total	1148.0	

The drug was blended with the two polymers and lactose and granulated with a solution of polyvinylpyrrolidone in water. The granules were dried, sized lubricated and compressed to tablets.

The tablets thus obtained were optionally film coated. Drug release from the tablets was tested in USP apparatus 2 at 60 rpm in pH 4.0 acetate buffer.

The results (Table 1.2) show that only 2.37% of rate controlling polymer was
5 able to control the release of the drug over an extended period of time.

Table 1.2

Time (h)	Cumulative Percent drug released
1	11
2	19
4	35
6	51
10	76

10 **EXAMPLE 2**

The present example describes clarithromycin controlled release tablets made using 3.23% of total rate controlling cellulosic ether polymer (a mixture of 4000 and 15000 cps viscosity grade hydroxypropyl methylcellulose)

15

Table 2.1

Ingredients	mg/tablet	Percent w/w of composition
Clarithromycin	1000.0	86.1
Methocel K15 MCR®	25	2.15
Methocel K 4 MCR®	12.5	1.08
Lactose	50.0	4.3
Sodium stearyl fumarate	20.0	1.72
Magnesium stearate	12.5	1.08
Talc	10.0	0.86
Colloidal silicon dioxide	0.5	0.43
Total	1161.5	

Clarithromycin was blended with the two polymers and lactose and wet granulated with water. The granules were dried, sized, lubricated and compressed
20 to tablets.

The tablets thus obtained were optionally film coated. Drug release from the tablets was tested in USP apparatus 2 at 80 rpm in pH 4.0 mixed phosphate buffer. The results obtained showed a controlled release of the drug from the dosage form (Table 2.2).

5

Table 2.2

Time (h)	Cumulative Percent drug released
1	20
2	35
4	65
6	83
8	86

EXAMPLE 3

- 10 Tinidazole controlled release tablets made according to the present example uses 1.2% of total rate controlling cellulosic ether polymer (a mixture of hydroxypropyl methylcellulose of 15,000 and 4,000 cps).

Table 3.1

Ingredients	mg/tablet	Percent w/w of composition
Tinidazol	1000.0	86.5
Methocel K15 MCR®	10.0	0.865
Methocel K4 MCR®	4.0	0.346
Starch 1500	75.0	6.5
Polyvinylpyrrolidone K30	15.0	1.3
Talc	10.0	0.865
Sodium stearyl fumarate	31.5	2.73
Colloidal silicon dioxide	5.0	0.43
Magnesium stearate	5.0	0.43
Total	1155.5	

15

The drug was blended with the two polymers and lactose and granulated with a solution of starch 1500 in water. The granules were dried, sized, lubricated and compressed to tablets.

20

The tablets thus obtained were optionally film coated. Drug release from the tablets was tested in USP apparatus 2 at 60 rpm in pH 4.0 acetate buffer and the

results showed a controlled release of the drug from the dosage form as given in Table 3.2.

Table 3.2

Time (h)	Cumulative Percent drug released
1	18
2	29
4	44
6	56
10	79

5

EXAMPLE 4

The present example describes 500 mg strength clarithromycin controlled release tablets made using 4.1% of total rate controlling polymer (a mixture of 4000 and 15000 cps viscosity grade hydroxypropyl methylcellulose)

10

Table 4.1

Ingredients	mg/tablet	Percent w/w of composition
Clarithromycin	500.0	58.82
Methocel K15 MCR®	7.0	0.82
Methocel K 4 MCR®	28.0	3.29
Lactose	263.0	30.94
PVP 30	12.0	1.41
Sodium stearyl fumarate	17.0	2.0
Magnesium stearate	3.0	0.35
Talc	15.0	1.76
Aerosil 200	5.0	0.58
Total	850.0	

15

The tablets thus obtained were optionally film coated. Drug release from the tablets was tested in USP apparatus 2 at 80 rpm in pH 4.0 mixed phosphate buffer and the results showed a controlled release of the drug from the dosage form as given in Table 4.2.

Table 4.2

Time (h)	Cumulative Percent drug released
1	19
2	35
4	62
6	83
8	92

5 EXAMPLE 5

A formulation was made using a combination of two viscosity grades (4000 cps and 15,000 cps) of HPMC polymer and sodium carboxymethyl cellulose (Sodium CMC). The total amount of rate controlling polymer used was only 2.39%.

10

Table 5.1

Ingredients	mg/tablet	Percent w/w of composition
Clarithromycin	1000.0	87.33
Methocel K15 MCR®	10.0	0.87
Methocel K 4 MCR®	9.0	0.78
Sodium CMC	8.5	0.74
Lactose	50.0	9.36
PVP 30	20	1.74
Sodium stearyl fumarate	31.5	2.7
Magnesium stearate	1.0	0.08
Talc	10.0	0.87
Aerosil 200	5.0	0.43
Total	1145.0	

The tablets thus obtained were optionally film coated. Drug release from the tablets was tested in USP apparatus 2 at 80 rpm in pH 4.0 mixed phosphate buffer and the results showed a controlled release of the drug from the dosage form as given in Table 5.2.

15

Table 5.2

Time (h)	Cumulative Percent drug released
1	20
2	45
4	77
8	91

EXAMPLE 6

5

A controlled release formulation for clarithromycin was made using sodium carboxymethyl cellulose (Sodium CMC) and hydroxypropyl cellulose as the rate controlling polymers. Only 2.5% of rate controlling polymer was used to control the drug release from the formulation.

10

Table 6.1

Ingredients	mg/tablet	Percent w/w of composition
Clarithromycin	1000.0	84.21
Sodium CMC	20.0	1.68
Hydroxypropyl cellulose L	10.0	0.84
Lactose	90.0	7.57
PVP 30	20.0	1.68
Sodium stearyl fumarate	31.5	2.65
Magnesium stearate	1.0	0.084
Talc	10.0	0.84
Aerosil 200	5.0	0.42
Total	1187.5	

The tablets thus obtained were optionally film coated. Drug release from the tablets was tested in USP apparatus 2 at 80 rpm in pH 4.0 mixed phosphate buffer and the results showed a controlled release of the drug from the dosage form as given in Table 6.2.

15

Table 6.2

Time (h)	Cumulative Percent drug released
1	20
2	43
4	75
6	88
8	91

EXAMPLE 7

Clarithromycin controlled release tablets were formulated using a combination of two viscosity grades (15,000 and 4,000 cps) of the rate controlling polymer hydroxypropyl methylcellulose sold under the trade name of Methocel K 4MCR® and Methocel K15 MCR®. The two polymers together comprised only 1.75% of the total tablet weight.

Table 7.1

Ingredients	Mg / tablet	Percent w/w of composition
Clarithromycin	1000.0	84.8
Methocel K15 MCR®	12.5	1.06
Methocel K 4 MCR®	8.0	0.68
Methocel E 50®	8.0	0.68
Lactose	75.0	6.36
Magnesium stearate	12.5	1.06
Talc	10.0	0.85
Colloidal Silicon Dioxide	5.0	0.43
Sodium stearyl fumarate	20.0	1.7
Total	1179.00	

Clarithromycin was blended with the two polymers and lactose and granulated with solution of methocel E50 in water. The granules were dried, sized, mixed with the remaining excipients and compressed to tablets.

The tablets thus obtained were optionally film coated. The drug release from the tablets was tested in USP apparatus 2 at 80 rpm pH 4.0 mixed phosphate buffer, and the results obtained show that only 1.75% of the rate controlling polymer was surprisingly able to control the release of the drug from the dosage form over an extended period of time (Table 1.2).

Table 7.2

Time (h)	Cumulative Percent drug released
1	23
2	38
4	70
6	93
8	99

EXAMPLE 8

According to the present example clarithromycin controlled release tablets were made using 2.35% of total rate controlling polymer (a mixture of 4000 and 5 15000 cps viscosity grade hydroxypropyl methylcellulose)

Table 8.1

Ingredients	Mg/tablet	Percent w/w of composition
Clarithromycin	1000.0	84.6
Methocel K15 MCR®	10.0	0.85
Methocel K 4 MCR®	17.5	1.5
Lactose	50.0	4.2
Polyvinyl pyrrolidone	25.0	2.1
Magnesium stearate	12.5	1.1
Talc	10.0	0.85
Colloidal Silicon Dioxide	5.0	0.40
Sodium stearyl fumarate	20.0	1.70
Total	1182.0	

Clarithromycin was blended with the two polymers and lactose and 10 granulated with a solution of polyvinyl pyrrolidone in water. The granules were dried, sized, lubricated and compressed to tablets.

The tablets thus obtained were optionally film coated. Drug release from the tablets was tested in USP apparatus 2 at 80 rpm in pH 4.0 mixed phosphate buffer. 15 The results obtained once again showed that 2.35% of the total rate controlling polymer was able to control the rate of drug release over a period of 10 hours (Table 2.2) .

Table 8.2

Time (h)	Cumulative Percent drug released
1	23
2	43
4	70
6	88
8	97

Pharmacokinetic Study

The formulations made in accordance with Examples 7 and 8 were subjected to bioavailability studies against clarithromycin 500 mg immediate release tablets administered in as BID dosage regimen and commercially available under the trade name Biaxin®.

A randomized, three treatment, three period, three sequence, single dose, crossover bioavailability study on clarithromycin XL 1000 mg tablets of the present invention administered once daily with Biaxin® 500 mg tablet of Abbott Laboratories administered 12 hourly in two doses to healthy, adult, male human subjects.

Values for clarithromycin pharmacokinetic parameters including C_{max}, and AUC_{0-t} were calculated. Table 9 summarizes the pharmacokinetic results obtained.

Table 9

Formulation	C _{max} (µg/ml)	AUC _{0-t} (µg.hr/ml)
A	2.669	37.248
B	3.025	33.389
Reference	3.401	37.945

20

Table 10 gives the point estimates of relative bioavailability (Test/Reference ratios) for the two one-sided test procedure from analysis of log transformed AUC (0-t) and C_{max}.

Table 10

Formulation comparison	C _{max} (μg/ml)	AUC _{0-t} (μg.hr/ml)
A/R	78.07	94.34
B/R	92.01	88.29

A : Formulation made in accordance with Example 8.

5 B : Formulation made in accordance with Example 7.

Reference : Biaxin® IR 500 mg tablets administered in a BID dosage regimen.

As can be seen from Tables 9 and 10 above, the two controlled release formulations A and B made in accordance with the present invention show a
10 bioavailability profile similar to the commercially available immediate release Biaxin® formulation administered in a BID dosage regimen.

In the next study, the single tablet formulation made in accordance to Example 8 was subjected to a comparative bioavailability study against the
15 commercially available Biaxin XL® tablets (two controlled release tablets to be administered together once a day).

Table 11 lists the pharmacokinetic parameters for the two clarithromycin XL formulations in healthy male subjects.

20

Table 11

Formulation comparison	C _{max} (μg/ml)	AUC _{0-t} (μg.hr/ml)
Biaxin XL®(2x500mg) tablets (Reference)	3.041	42.016
Clarithromycin XL 1000mg tablets (Test)	3.032	42.210

Table 12 gives the point estimates of the relative bioavailability and 90% confidence intervals from log transformed AUC_{0-t} and C_{max}.

Table 12

Formulation comparison	Cmax($\mu\text{g/ml}$)	AUC ₀₋₁ ($\mu\text{g.hr/ml}$)	AUC _{0-∞} ($\mu\text{g.hr/ml}$)
Test./Reference	99.33	99.15	103.39
90% confidence interval	81.5-121.0	87-112.9	91-114.8

The data given above shows that formulation of the present invention containing only 2.35% of a rate controlling polymer can surprisingly produce a
5 bioequivalent formulation (as required by the US FDA guidelines on bioequivalence) to Biaxin XL®, which is made using substantially higher quantities of rate controlling polymers.

10 While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

CLAIMS :

1. A controlled release formulation, suitable for once daily administration, comprising a pharmaceutically effective amount of at least one drug having a water solubility of less than one part per 30 parts water, and from about 0.1% to about 4.5% w/w of one or more rate controlling high viscosity cellulosic ether polymers.
5
2. The controlled release formulation of claim 1 wherein the drug comprises from about 10% w/w to about 90% w/w of the composition.
10
3. The controlled release formulation of claim 1 wherein the drug preferably comprises from about 50% w/w to about 90% w/w of the composition.
4. The controlled release formulation of claim 1 wherein the drug is selected from those belonging to the therapeutic categories of analgesics, anthelmintics, cardiovasculars, antibacterials, bronchodilators, anti-asthmatics, gastrointestinal drugs, antidiabetics, antiprotozoals, antivirals and antiepileptics.
15
20
5. The controlled release formulation of claim 1 wherein the drug is selected from the group consisting of Etodolac, Albendazole, Chlorothiazide, Ciprofloxacin, Erythromycin and its derivatives, Doxyfylline, Cimetidine, Tolbutamide, Tinidazol, Aciclovir, Carbamazepine, and their pharmaceutically acceptable salts and esters.
25
6. The controlled release formulation of claim 1 wherein the cellulosic ether polymers are selected from amongst hydroxypropyl methylcellulose, hydroxypropylcellulose, carboxy methylcellulose, hydroxy ethylcellulose, sodium carboxy methylcellulose, and mixtures thereof.
30
7. The controlled release formulation of claim 6 wherein the cellulosic ether polymer is hydroxypropyl methylcellulose either alone or in combination with other cellulosic ether polymers.

8. The controlled release formulation of claim 7 wherein hydroxypropyl methylcellulose has a viscosity of 4000 cps or more.
- 5 9. The controlled release formulation of claim 8, wherein the high viscosity hydroxypropyl methylcellulose polymers are preferably selected from amongst those having a viscosity of 4000 cps, 15,000 cps, and mixtures thereof.
- 10 10. The controlled release formulation of claim 1 wherein the formulation may additionally contain other pharmaceutically acceptable excipients such as fillers, binders, and lubricants.
- 15 11. The controlled release formulation of claim 10 wherein the filler is selected from the group consisting of monosaccharides, disaccharides, polysaccharides, starches, celluloses, and mixtures thereof.
- 20 12. The controlled release formulation of claim 10 wherein the filler comprises from about 5% w/w to about 15% w/w of the composition.
- 25 13. The controlled release formulation of claim 10 wherein the lubricant is selected from amongst the group consisting of talc, calcium stearate, magnesium stearate, polyethylene glycol, sodium stearyl fumarate, and mixtures thereof.
- 30 14. The controlled release formulation of claim 10 wherein the binder is selected from amongst polyvinyl pyrrolidone, starch, low viscosity grade hydroxypropyl methylcellulose, hydroxyethyl cellulose, and the like.
15. The controlled release formulation of claim 1 wherein the formulation is a tablet or a capsule.
16. The controlled release formulation of claim 15 wherein the formulation is preferably a tablet.

17. The controlled release formulation of claim 15 wherein the tablet is optionally film coated.
- 5 18. The controlled release monolithic tablet formulation comprising 100-1300 mg of drug and 0.1% to 4.5% w/w of one or more than one rate controlling cellulosic ether polymer wherein the total tablet weight is not more than 1500 mg.
- 10 19. The controlled release monolithic tablet formulation of claim 18 comprising about 1000 mg drug wherein the total weight is preferably not more than 1300 mg.
- 15 20. The controlled release monolithic tablet formulation of claim 18 wherein the tablet comprises a drug with low solubility in water and 0.1% w/w to 4.5% w/w of one or more than one rate controlling polymer wherein the rate controlling polymers is a cellulose ether polymer.
- 20 21. The controlled release tablet formulation of claim 18 wherein the rate controlling polymer is hydroxypropyl methylcellulose of viscosity grades 4000 cps, 15,000 cps, and mixtures thereof.
- 25 22. An extended release formulation comprising 1000 mg of clarithromycin and pharmaceutically acceptable excipients, wherein the total weight of the dosage unit is not more than 1500 mg.
- 30 23. An extended release pharmaceutical unit dose composition of 1000 mg of clarithromycin comprising from about 0.1% to about 4.5% weight of a high viscosity hydroxypropyl methylcellulose polymer, so that when ingested orally, the composition provides area under the concentration-time curve and the maximum plasma concentration substantially equivalent to the commercially available daily dose of two 500 mg strength clarithromycin tablets administered together.

- 5 24. A unit dose extended release tablet composition comprising 1000 mg of clarithromycin and from about 0.1% to about 4.5% by weight of high viscosity hydroxypropyl methylcellulose polymer wherein the 90% confidence interval of clarithromycin area under the concentration-time curve and maximum plasma concentration is within the interval 0.80-1.25 when compared with commercially available daily dose of two 500 mg strength clarithromycin tablets administered together.
- 10 25. The extended release composition of claim 23 wherein the high viscosity hydroxypropyl methylcellulose polymers comprise one or more than one polymer having a viscosity of 4000 cps or more.
- 15 26. The extended release composition of claim 23 wherein clarithromycin comprises from about 10% to about 90% w/w of the composition.
27. The extended release composition of claim 25 wherein clarithromycin preferably comprises from about 50% w/w to about 90% w/w of the composition.

INTERNATIONAL SEARCH REPORT

In Application No
PCT/IB 02/00175A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/20 A61K31/7048

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 571 333 A (HSIAO CHARLES H ET AL) 18 February 1986 (1986-02-18) column 4, line 36 - line 47 column 5, line 26 - line 49 column 6, line 4 -column 1, line 4; claims 1-3 ---	1-4, 6-10,13, 15-21
X	WO 00 15198 A (STANIFORTH JOHN H ;SEN HIMADRI (IN); TALWAR NARESH (IN); RANBAXY L) 23 March 2000 (2000-03-23) page 1, paragraph 1 page 6, line 18 -page 10, line 21 page 13, line 11 -page 22, line 18; example 10 --- -/--	1-6,10, 13, 15-18,20

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

24 June 2002

Date of mailing of the international search report

04/07/2002

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Marttin, E

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/IB 02/00175

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 200 193 A (RADEBAUGH GALEN W ET AL) 6 April 1993 (1993-04-06) column 3, line 1 -column 4, line 2 column 4, line 48 -column 5, line 21 column 6, line 14 - line 28; claims 1,3; examples 3-12 ----	1-5,10, 11, 13-18,20
X	WO 00 07570 A (DICKINSON JEFFREY ;MAKWANA JAYANTILAL VITHAL (GB); BOOTS CO PLC (G) 17 February 2000 (2000-02-17) page 11, line 14 - line 26 page 13, line 23 - line 26; example 37 ----	1-4,6,7, 10, 15-18,20
X	WO 01 52833 A (GARDNER REBECCA ;CORTENDO AB (SE); LANDH TOMAS (SE); OESTHOLM IVAN) 26 July 2001 (2001-07-26) claims 1,2,23-25; figure 16; example 10; table 7 ----	1,2,4-7, 15-18,20
X	US 5 009 897 A (BRINKER DALE R ET AL) 23 April 1991 (1991-04-23) column 1, line 31 - line 40 column 2, line 30 -column 3, line 3; example 3 ----	1-7,10, 11, 13-18,20
X	US 4 119 723 A (WYBURN-MASON ROGER) 10 October 1978 (1978-10-10) column 5, line 14 - line 31; example 1 ----	1-7,10, 11, 13-18,20
E,L	WO 02 17885 A (KUMAR MANOJ ;RAMPAL ASHOK (IN); RANBAXY LAB LTD (IN); RAGHUVANSHI) 7 March 2002 (2002-03-07) L: Priority page 4, line 19 -page 6, line 11 page 7, line 6 - line 9 page 8, line 17 -page 9, line 17 claims 1-5,9,11,18,19,21-24; examples 3,4 -----	1-8,11, 13-18, 22-24, 26,27

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/IB 02/00175

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4571333	A	18-02-1986	AT 389225 B	10-11-1989
			AT 191084 A	15-04-1989
			AU 552080 B2	22-05-1986
			AU 1801183 A	20-12-1984
			BE 899885 A1	12-12-1984
			CA 1204671 A1	20-05-1986
			CH 643455 A5	15-06-1984
			DE 3329265 A1	20-12-1984
			DK 553683 A ,B,	15-12-1984
			FI 842400 A ,B,	15-12-1984
			FR 2547498 A1	21-12-1984
			GB 2141338 A ,B	19-12-1984
			HK 95590 A	23-11-1990
			IE 55585 B1	07-11-1990
			IT 1200967 B	27-01-1989
			JP 1933332 C	26-05-1995
			JP 6062404 B	17-08-1994
			JP 60072813 A	24-04-1985
			LU 84962 A1	28-12-1983
			NL 8302842 A ,B,	02-01-1985
			NO 842362 A ,B,	17-12-1984
			NZ 204708 A	14-12-1984
			PH 17827 A	07-01-1985
			SE 454565 B	16-05-1988
			SE 8304393 A	15-12-1984
			SG 80990 G	23-11-1990
			US 4803079 A	07-02-1989
			ZA 8305591 A	27-03-1985
WO 0015198	A	23-03-2000	AU 1779499 A	03-04-2000
			BG 105339 A	30-11-2001
			BR 9913696 A	09-10-2001
			CN 1325299 T	05-12-2001
			CZ 20010901 A3	15-08-2001
			EP 1107741 A1	20-06-2001
			HR 20010187 A1	30-04-2002
			WO 0015198 A1	23-03-2000
			NO 20011276 A	10-05-2001
			PL 346798 A1	25-02-2002
			SK 3472001 A3	08-10-2001
			TR 200100731 T2	21-06-2001
			ZA 9905839 A	28-03-2000
US 5200193	A	06-04-1993	US 4806359 A	21-02-1989
			US 5462747 A	31-10-1995
			AT 86479 T	15-03-1993
			AU 604110 B2	06-12-1990
			AU 1477488 A	27-10-1988
			AU 603675 B2	22-11-1990
			AU 1719788 A	02-12-1988
			CA 1310272 A1	17-11-1992
			DE 3865077 D1	31-10-1991
			DE 3879080 D1	15-04-1993
			DE 3879080 T2	15-07-1993
			EP 0290168 A1	09-11-1988
			EP 0312581 A1	26-04-1989
			ES 2039277 T3	16-09-1993
			GR 88100258 A ,B	31-01-1989

Form PCT/ISA/210 (patent family annex) (July 1992)

INTERNATIONAL SEARCH REPORT

In 1st Application No
PCT/IB 02/00175

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5200193	A		HK 22892 A	03-04-1992
			IE 62786 B	22-02-1995
			IN 165929 A1	10-02-1990
			JP 2519296 B2	31-07-1996
			JP 63280021 A	17-11-1988
			JP 1503070 T	19-10-1989
			JP 2776856 B2	16-07-1998
			KR 9607750 B1	12-06-1996
			KR 9606061 B1	08-05-1996
			NO 176203 B	14-11-1994
			NO 175185 B	06-06-1994
			NZ 224278 A	26-09-1990
			PH 25176 A	27-03-1991
			PT 87285 A ,B	01-05-1988
			SG 104091 G	14-02-1992
			WO 8808299 A1	03-11-1988
			ZA 8802827 A	27-12-1989
WO 0007570	A	17-02-2000	AU 6190499 A	28-02-2000
			BG 105303 A	30-11-2001
			BR 9912706 A	29-01-2002
			CN 1321084 T	07-11-2001
			WO 0007570 A1	17-02-2000
			EP 1100472 A1	23-05-2001
			NO 20010537 A	14-03-2001
			PL 345811 A1	14-01-2002
			SK 1752001 A3	06-08-2001
			TR 200100611 T2	22-10-2001
WO 0152833	A	26-07-2001	AU 2693401 A	31-07-2001
			WO 0152833 A1	26-07-2001
			US 2002055512 A1	09-05-2002
US 5009897	A	23-04-1991	AT 82497 T	15-12-1992
			AU 3656189 A	04-01-1990
			CA 1335258 A1	18-04-1995
			DE 68903536 D1	24-12-1992
			DE 68903536 T2	22-04-1993
			EP 0347748 A2	27-12-1989
			ES 2052816 T3	16-07-1994
			GR 3006537 T3	30-06-1993
			IE 63242 B	05-04-1995
			JP 2045418 A	15-02-1990
			JP 2862567 B2	03-03-1999
			US 5169642 A	08-12-1992
			US 5268182 A	07-12-1993
US 4119723	A	10-10-1978	CA 1109797 A1	29-09-1981
WO 0217885	A	07-03-2002	WO 0217885 A2	07-03-2002

This Page Blank (uspto)